Lv3
314 积分 2023-10-08 加入
Ivonescimab versus pembrolizumab for PD-L1-positive non-small cell lung cancer (HARMONi-2): a randomised, double-blind, phase 3 study in China
21小时前
待确认
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
22小时前
已完结
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial
22小时前
已完结
Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial
23小时前
已完结
Extracellular targeted protein degradation: an emerging modality for drug discovery
20天前
已完结
The present and future of bispecific antibodies for cancer therapy
1个月前
已完结
Tislelizumab combined with nab-paclitaxel and cisplatin as the more effective chemoimmunotherapy strategy in the neoadjuvant treatment of locally advanced thoracic esophageal squamous cell carcinoma: A prospective, two-cohort, phase 2 trial
1个月前
已完结
Le fruquintinib dans le cancer colorectal métastatique en échec des traitements standardsFruquintinib for patients with metastatic colorectal cancer previously treated with standard treatments
2个月前
已关闭
晚期非小细胞肺癌免疫治疗研究进展
3个月前
已完结
Non-small-cell lung cancer
3个月前
已完结
皖公网安备34019202002308
